Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis
MetadataShow full item record
AbstractThe World Health Organization recommended two new drugs, bedaquiline (BDQ) and delamanid (DLM), for the treatment of multidrug-resistant tuberculosis (MDR-TB) in 2013 and 2014, respectively. An estimated one third of patients with MDR-TB would benefit from the inclusion of these drugs in their treatment regimens.
- Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries.
- Authors: Guglielmetti L, Hewison C, Avaliani Z, Hughes J, Kiria N, Lomtadze N, Ndjeka N, Setkina S, Shabangu A, Sikhondze W, Skrahina A, Veziris N, Furin J
- Issue date: 2017 Feb 1
- Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis.
- Authors: Furin J, Brigden G, Lessem E, Rich M, Vaughan L, Lynch S
- Issue date: 2016 Mar
- Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.
- Authors: D'Ambrosio L, Centis R, Tiberi S, Tadolini M, Dalcolmo M, Rendon A, Esposito S, Migliori GB
- Issue date: 2017 Jul
- Authors: Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, Knight G, Murray M, Nardell E, Rubin E, Salomon J, Vassall A, Volchenkov G, White R, Wilson D, Yadav P, Holmes KK, Bertozzi S, Bloom BR, Jha P
- Issue date: 2017 Nov 3
- New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid.
- Authors: Brigden G, Hewison C, Varaine F
- Issue date: 2015